Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Non-Current Deffered Revenue (2016 - 2025)

Dare Bioscience (DARE) has disclosed Non-Current Deffered Revenue for 8 consecutive years, with $1.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non-Current Deffered Revenue changed 0.0% year-over-year to $1.0 million, compared with a TTM value of $1.0 million through Sep 2025, changed 0.0%, and an annual FY2024 reading of $1.0 million, changed 0.0% over the prior year.
  • Non-Current Deffered Revenue was $1.0 million for Q3 2025 at Dare Bioscience, roughly flat from $1.0 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $1.2 million in Q2 2023 and bottomed at $1.0 million in Q1 2021.
  • Average Non-Current Deffered Revenue over 5 years is $1.0 million, with a median of $1.0 million recorded in 2021.
  • The sharpest move saw Non-Current Deffered Revenue rose 20.52% in 2023, then fell 17.03% in 2024.
  • Year by year, Non-Current Deffered Revenue stood at $1.0 million in 2021, then changed by 0.0% to $1.0 million in 2022, then changed by 0.0% to $1.0 million in 2023, then changed by 0.0% to $1.0 million in 2024, then changed by 0.0% to $1.0 million in 2025.
  • Business Quant data shows Non-Current Deffered Revenue for DARE at $1.0 million in Q3 2025, $1.0 million in Q2 2025, and $1.0 million in Q1 2025.